Luan César Silva1, Gabriell Bonifácio Borgato1, Vivian Petersen Wagner2, Manoela Domingues Martins1,3, Guilherme Zweig Rocha1, Márcio Ajudarte Lopes1, Alan Roger Santos-Silva1, Gilberto de Castro Júnior4, Luiz Paulo Kowalski5, Jacques E Nor6, Cristiane H Squarize7, Rogerio Moraes Castilho7, Pablo Agustin Vargas1. 1. Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, São Paulo, Brazil. 2. Academic Unit of Oral and Maxillofacial Medicine and Pathology, Department of Clinical Dentistry, University of Sheffield, Sheffield, UK. 3. Department of Oral Pathology, School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. 4. Clinical Oncology Service, São Paulo State Cancer Institute (ICESP), School of Medicine of the University of São Paulo, São Paulo, Brazil. 5. Department of Head and Neck Surgery, Faculty of Medicine, Head and Neck Surgery and Otorhinolaryngology Department, A C Camargo Cancer Center, Universidade de São Paulo, São Paulo, Brazil. 6. Department of Cariology, Restorative Sciences, Endodontics, School of Dentistry, University of Michigan, Ann Arbor, Michigan, USA. 7. Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, Michigan, USA.
Abstract
AIM: To evaluate the potential use of Cephaeline as a therapeutic strategy to manage mucoepidermoid carcinomas (MEC) of the salivary glands. MATERIAL AND METHODS: UM-HMC-1, UM-HMC-2, and UM-HMC-3A MEC cell lines were used to establish the effects of Cephaeline over tumor viability determined by MTT assay. In vitro wound healing scratch assays were performed to address cellular migration while immunofluorescence staining for histone H3 lysine 9 (H3k9ac) was used to identify the acetylation status of tumor cells upon Cephaeline administration. The presence of cancer stem cells was evaluated by the identification of ALDH enzymatic activity by flow cytometry and through functional assays using in vitro tumorsphere formation. RESULTS: A single administration of Cephaeline resulted in reduced viability of MEC cells along with the halt on tumor growth and cellular migration potential. Administration of Cephaeline resulted in chromatin histone acetylation as judged by the increased levels of H3K9ac and disruption of tumorspheres formation. Interestingly, ALDH levels were increased in UM-HMC-1 and UM-HMC-3A cell lines, while UM-HMC-2 showed a reduced enzymatic activity. CONCLUSION: Cephaeline has shown anti-cancer properties in all MEC cell lines tested by regulating tumor cells' viability, migration, proliferation, and disrupting the ability of cancer cells to generate tumorspheres.
AIM: To evaluate the potential use of Cephaeline as a therapeutic strategy to manage mucoepidermoid carcinomas (MEC) of the salivary glands. MATERIAL AND METHODS: UM-HMC-1, UM-HMC-2, and UM-HMC-3A MEC cell lines were used to establish the effects of Cephaeline over tumor viability determined by MTT assay. In vitro wound healing scratch assays were performed to address cellular migration while immunofluorescence staining for histone H3 lysine 9 (H3k9ac) was used to identify the acetylation status of tumor cells upon Cephaeline administration. The presence of cancer stem cells was evaluated by the identification of ALDH enzymatic activity by flow cytometry and through functional assays using in vitro tumorsphere formation. RESULTS: A single administration of Cephaeline resulted in reduced viability of MEC cells along with the halt on tumor growth and cellular migration potential. Administration of Cephaeline resulted in chromatin histone acetylation as judged by the increased levels of H3K9ac and disruption of tumorspheres formation. Interestingly, ALDH levels were increased in UM-HMC-1 and UM-HMC-3A cell lines, while UM-HMC-2 showed a reduced enzymatic activity. CONCLUSION: Cephaeline has shown anti-cancer properties in all MEC cell lines tested by regulating tumor cells' viability, migration, proliferation, and disrupting the ability of cancer cells to generate tumorspheres.
Authors: Pablo Agustin Vargas; Ren Gerhard; Vergílius J F Araújo Filho; Inês Vieira de Castro Journal: Rev Hosp Clin Fac Med Sao Paulo Date: 2003-02-17
Authors: Andrés Coca-Pelaz; Juan P Rodrigo; Asterios Triantafyllou; Jennifer L Hunt; Alessandra Rinaldo; Primož Strojan; Missak Haigentz; William M Mendenhall; Robert P Takes; Vincent Vander Poorten; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2014-04-26 Impact factor: 2.503
Authors: Kshitij Parag-Sharma; Jason Tasoulas; Adele M Musicant; Carlos H Viesi do Nascimento-Filho; Zhichuan Zhu; Chloe Twomey; Pengda Liu; Rogerio M Castilho; Antonio L Amelio Journal: Oral Oncol Date: 2021-02-11 Impact factor: 5.337
Authors: Vivian P Wagner; Marco A T Martins; Manoela D Martins; Kristy A Warner; Liana P Webber; Cristiane H Squarize; Jacques E Nör; Rogerio M Castilho Journal: Oncotarget Date: 2016-11-08
Authors: Vivian P Wagner; Manoela D Martins; Marco A T Martins; Luciana O Almeida; Kristy A Warner; Jacques E Nör; Cristiane H Squarize; Rogerio M Castilho Journal: Sci Rep Date: 2018-02-01 Impact factor: 4.379